URGN vs. NVDA

Last updated Apr 2, 2026

Compare and contrast key facts about UroGen Pharma Ltd. (URGN) and NVIDIA Corporation (NVDA).

Performance

URGN vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in UroGen Pharma Ltd. (URGN) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

URGN vs. NVDA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
URGN UroGen Pharma Ltd.	-19.13%	119.91%	-29.00%	69.11%	-6.73%	-47.23%	-46.00%	-22.50%	15.72%	166.17%
NVDA NVIDIA Corporation	-5.76%	38.92%	171.25%	239.02%	-50.26%	125.48%	122.30%	76.94%	-30.82%	86.82%

Fundamentals

Market Cap URGN : $932.42M NVDA : $4.29T
EPS URGN : -$3.18 NVDA : $4.90
PS Ratio URGN : 8.34 NVDA : 19.95
Total Revenue (TTM) URGN : $109.79M NVDA : $215.94B
Gross Profit (TTM) URGN : $97.34M NVDA : $153.46B
EBITDA (TTM) URGN : -$127.69M NVDA : $144.55B

Returns By Period

In the year-to-date period, URGN achieves a -19.13% return, which is significantly lower than NVDA's -5.76% return.

URGN

• 1D: 5.34%
• 1M: -0.42%
• YTD: -19.13%
• 6M: 6.31%
• 1Y: 78.17%
• 3Y*: 27.03%
• 5Y*: -0.71%
• 10Y*: —

NVDA

• 1D: 0.77%
• 1M: -3.68%
• YTD: -5.76%
• 6M: -6.13%
• 1Y: 59.59%
• 3Y*: 85.01%
• 5Y*: 66.40%
• 10Y*: 69.75%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

URGN vs. NVDA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

URGN

URGN Risk / Return Rank: 69
URGN Sharpe Ratio Rank: 65
URGN Sortino Ratio Rank: 73
URGN Omega Ratio Rank: 76
URGN Calmar Ratio Rank: 64
URGN Martin Ratio Rank: 66

NVDA

NVDA Risk / Return Rank: 82
NVDA Sharpe Ratio Rank: 83
NVDA Sortino Ratio Rank: 80
NVDA Omega Ratio Rank: 77
NVDA Calmar Ratio Rank: 86
NVDA Martin Ratio Rank: 84

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

URGN vs. NVDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for UroGen Pharma Ltd. (URGN) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	URGN	NVDA	Difference
Sharpe ratio Return per unit of total volatility	0.69	1.45	-0.76
Sortino ratio Return per unit of downside risk	1.78	2.14	-0.36
Omega ratio Gain probability vs. loss probability	1.27	1.27	0.00
Calmar ratio Return relative to maximum drawdown	1.08	3.08	-2.00
Martin ratio Return relative to average drawdown	3.00	7.73	-4.73
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

URGN vs. NVDA - Sharpe Ratio Comparison

The current URGN Sharpe Ratio is 0.69, which is lower than the NVDA Sharpe Ratio of 1.45. The chart below compares the historical Sharpe Ratios of URGN and NVDA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	URGN	NVDA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.69	1.45	-0.76
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.01	1.29	-1.30
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.40	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.04	0.61	-0.57

Correlation

The correlation between URGN and NVDA is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

URGN vs. NVDA - Dividend Comparison

URGN has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.02%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
URGN UroGen Pharma Ltd.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVDA NVIDIA Corporation	0.02%	0.02%	0.03%	0.03%	0.11%	0.05%	0.12%	0.27%	0.46%	0.29%	0.45%	1.20%

Drawdowns

URGN vs. NVDA - Drawdown Comparison

The maximum URGN drawdown since its inception was -93.98%, roughly equal to the maximum NVDA drawdown of -89.72%. Use the drawdown chart below to compare losses from any high point for URGN and NVDA.

Drawdown Indicators

	URGN	NVDA	Difference
Max Drawdown Largest peak-to-trough decline	-93.98%	-89.72%	-4.26%
Max Drawdown (1Y) Largest decline over 1 year	-66.24%	-20.21%	-46.03%
Max Drawdown (5Y) Largest decline over 5 years	-82.64%	-66.34%	-16.30%
Max Drawdown (10Y) Largest decline over 10 years	—	-66.34%	—
Current Drawdown Current decline from peak	-71.01%	-15.10%	-55.91%
Average Drawdown Average peak-to-trough decline	-61.55%	-36.40%	-25.15%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.79%	8.05%	+15.74%

Volatility

URGN vs. NVDA - Volatility Comparison

UroGen Pharma Ltd. (URGN) has a higher volatility of 15.35% compared to NVIDIA Corporation (NVDA) at 10.43%. This indicates that URGN's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	URGN	NVDA	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.35%	10.43%	+4.92%
Volatility (6M) Calculated over the trailing 6-month period	49.37%	25.79%	+23.58%
Volatility (1Y) Calculated over the trailing 1-year period	113.74%	41.42%	+72.32%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	91.48%	51.72%	+39.76%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	79.73%	49.84%	+29.89%

Financials

URGN vs. NVDA - Profitability Comparison

The chart below illustrates the profitability comparison between UroGen Pharma Ltd. and NVIDIA Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

URGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, UroGen Pharma Ltd. reported a gross profit of 34.55M and revenue of 37.84M. Therefore, the gross margin over that period was 91.3%.

NVDA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, NVIDIA Corporation reported a gross profit of 51.09B and revenue of 68.13B. Therefore, the gross margin over that period was 75.0%.

URGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, UroGen Pharma Ltd. reported an operating income of -19.12M and revenue of 37.84M, resulting in an operating margin of -50.5%.

NVDA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, NVIDIA Corporation reported an operating income of 44.30B and revenue of 68.13B, resulting in an operating margin of 65.0%.

URGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, UroGen Pharma Ltd. reported a net income of -26.36M and revenue of 37.84M, resulting in a net margin of -69.7%.

NVDA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, NVIDIA Corporation reported a net income of 42.96B and revenue of 68.13B, resulting in a net margin of 63.1%.